You are viewing: Rest Of Asia Pacific Humanized Mouse and Rat Model Market analysis

The Rest Of Asia Pacific Humanized Mouse and Rat Model Market was valued at $3.7 Million in 2025 and projected to reach to $5.1 Million by 2030, representing a compound annual growth rate of CAGR 6.6%. The Rest Of Asia Pacific humanized mouse and rat model market is positioned for consistent growth as regional pharmaceutical companies and research institutions prioritize preclinical testing capabilities.

Rest Of Asia Pacific Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Asia Pacific Humanized Mouse and Rat Model Market Trends and Insights

  • Rest Of Asia Pacific represents a developing segment within the broader Asia Pacific region, driven by increasing investment in preclinical research infrastructure and pharmaceutical development.
  • The region's growth trajectory reflects rising adoption of humanized animal models for drug discovery and toxicology testing across emerging markets. Rest Of Asia Pacific's 6.6% compound annual growth rate (CAGR) reflects moderate but consistent market expansion through 2030.
  • Rest Of Asia Pacific benefits from growing biotechnology sectors, government support for life sciences research, and partnerships with global pharmaceutical companies seeking cost-effective research solutions.
  • The market dynamics in Rest Of Asia Pacific are shaped by improving laboratory capabilities, regulatory harmonization efforts, and increased funding for translational medicine initiatives. Rest Of Asia Pacific's competitive landscape includes both regional suppliers and international vendors establishing local presence.
  • Rest Of Asia Pacific continues to attract investment as researchers recognize the value of humanized models in reducing development timelines and improving clinical trial success rates..

Key Market Statistics

  • CAGR (2025-2030) CAGR 6.6%
  • Market Size, 2025 ~USD 3.7 Million
  • Forecast, 2030 ~USD 5.1 Million
  • Country Rest Of Asia Pacific

Rest Of Asia Pacific Humanized Mouse and Rat Model Market Overview

Steady Regional Growth :

Rest Of Asia Pacific humanized mouse and rat model market is valued at $3.7 million in 2025, with a projected CAGR of 6.6% through 2030, reaching $5.1 million by forecast end.

Preclinical Research Infrastructure Expansion :

Increasing investments in research facilities and laboratory capabilities across Rest Of Asia Pacific countries are driving demand for advanced humanized animal models in drug development pipelines.

Pharmaceutical Development Acceleration :

Growing pharmaceutical and biotechnology sectors in emerging Rest Of Asia Pacific markets are adopting humanized mouse and rat models for efficacy and safety testing before clinical trials.

Developing Market Segment :

Rest Of Asia Pacific represents a developing but promising segment within the broader Asia Pacific region, with untapped potential for market expansion and research collaboration opportunities.

Rest Of Asia Pacific Humanized Mouse and Rat Model Market Dynamics

  • Government initiatives supporting life sciences research and increasing R&D budgets are creating favorable conditions for market expansion.
  • The region's lower operational costs compared to developed markets make it an attractive hub for outsourced preclinical research services. By 2030, the market is expected to reach $5.1 million, driven by rising demand from contract research organizations and academic institutions.
  • Collaborations with global pharmaceutical companies and technology transfer initiatives will further accelerate adoption.
  • However, regulatory standardization and infrastructure development remain key factors that will influence the pace of market growth in Rest Of Asia Pacific..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Rest Of Asia Pacific's humanized mouse and rat model market is valued at $3.7 million in 2025 and expected to reach $5.1 million by 2030, representing a 6.6% CAGR.
    • Rest Of Asia Pacific is experiencing moderate but consistent growth driven by expanding biotechnology sectors and increased pharmaceutical R&D investment in emerging markets.
    • Rest Of Asia Pacific benefits from improving laboratory infrastructure, regulatory support, and cost advantages that attract global pharmaceutical partnerships.
    • Rest Of Asia Pacific's market expansion is supported by growing recognition of humanized models' value in accelerating drug development and reducing clinical trial failures.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    Rest Of Asia Pacific Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    Target Audience

    • Pharmaceutical & Biotech Companies : Need Rest Of Asia Pacific market insights to identify outsourcing opportunities, establish regional R&D centers, and understand preclinical testing demand from emerging pharmaceutical markets in the region.
    • Contract Research Organizations (CROs) : Require detailed Rest Of Asia Pacific market data to assess expansion potential, identify client bases, and develop service offerings tailored to regional pharmaceutical and academic research institutions.
    • Research Institutions & Universities : Need market intelligence on Rest Of Asia Pacific to secure funding, benchmark research capabilities, and understand collaboration opportunities with regional and global pharmaceutical partners.
    • Investors & Private Equity Firms : Seek Rest Of Asia Pacific market analysis to evaluate investment opportunities in biotech infrastructure, research facilities, and emerging life sciences companies in this developing segment.
    • Government & Regulatory Bodies : Require Rest Of Asia Pacific market data to develop science policies, allocate research funding, and establish regulatory frameworks supporting preclinical research infrastructure development.

    Key Companies in the Rest Of Asia Pacific Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuation data specific to Rest Of Asia Pacific ($3.7M in 2025, $5.1M in 2030) with detailed CAGR analysis to support investment and expansion decisions in this developing segment.
    • Competitive Landscape Intelligence : Identify key players, market share distribution, and competitive strategies unique to Rest Of Asia Pacific, enabling strategic positioning and partnership opportunities in this emerging market.
    • Growth Driver Analysis : Understand region-specific factors driving 6.6% CAGR, including infrastructure investments, pharmaceutical sector growth, and research funding trends exclusive to Rest Of Asia Pacific countries.
    • Investment & Expansion Strategy : Leverage Rest Of Asia Pacific-focused insights to identify high-potential sub-markets, assess regulatory environments, and develop targeted go-to-market strategies for this developing region.
    • Stakeholder Decision Support : Provide pharmaceutical companies, CROs, and research institutions with Rest Of Asia Pacific-specific data to justify R&D investments, facility expansion, and resource allocation decisions.

    Frequently asked questions

    What is the market size of humanized mouse and rat models in Rest Of Asia Pacific?

    Rest Of Asia Pacific's humanized mouse and rat model market was valued at $3.7 million in 2025 and is forecast to reach $5.1 million by 2030.

    What is the growth rate for Rest Of Asia Pacific's humanized mouse and rat model market?

    Rest Of Asia Pacific's market is growing at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2030.

    What factors are driving growth in Rest Of Asia Pacific's humanized model market?

    Rest Of Asia Pacific's growth is driven by expanding biotechnology sectors, increased pharmaceutical R&D investment, improving laboratory infrastructure, and cost advantages that attract global partnerships.

    How does Rest Of Asia Pacific compare to other Asia Pacific regions?

    Rest Of Asia Pacific represents a developing segment within Asia Pacific with moderate growth potential, characterized by emerging market dynamics and increasing research infrastructure investment.

    What applications are driving demand in Rest Of Asia Pacific?

    Rest Of Asia Pacific's demand is driven by drug discovery, toxicology testing, translational medicine research, and clinical trial support applications across pharmaceutical and biotechnology companies.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status